In a genetic heart disease, mitochondria change before symptoms do — and a plant compound blunted the shift, in mice

Edited by Samael A. Tejada, Founder & Editor-in-Chief

The deadliest stage of this disease is the one nobody can feel. This study's contribution is a clock: it orders the molecular events of the first three weeks, puts mitochondria near the start rather than the wreckage at the end, and tests whether pushing back at that early stage moves the whole pattern. In mice, it did — which is the beginning of an argument, not the end of one.

How was the concealed stage mapped?

The team used adult mice with an inducible, heart-cell-specific Pkp2 knockout, triggered with tamoxifen, and collected right and left ventricular tissue separately at 7, 10, 14, 17 and 21 days. PKP2 protein fell progressively in both ventricles — to about half of control by day 10 and a quarter by day 21. The proteomics were deep: more than 4,000 proteins per sample, 6,527 unique proteins in total across 72 samples. Against that background, the earliest coordinated changes included loss of desmosomal components in both ventricles and a distinctive mitochondrial pattern — expansion of mitochondrial mass coupled to selective decreases in key metabolic machinery — with functional oxidative stress manifesting later, a sequence the authors describe as progressive in magnitude and scope.

What did honokiol do — and how sure is the mechanism?

From day 7, knockout mice received honokiol or vehicle for 14 days. In right-ventricular tissue at day 21, honokiol shifted protein abundances in directions opposite to the disease trajectory: proteins the disease pushed down were relatively preserved, and proteins it pushed up were reciprocally reduced, across multiple clusters. Thermal proteome profiling in isolated mouse heart cells resolved the melting behaviour of more than 6,700 proteins and found 60 with significant stability shifts on honokiol, including inner-mitochondrial-membrane proteins such as the complex III subunit UQCR11, with oxidative phosphorylation — particularly complex III — among the strongest signatures. Notably, sirtuin-3 itself showed no significant thermal shift, and the authors observe that honokiol's direct binding to SIRT3 may act as a net steady-state inhibitor — a complication for the simple 'SIRT3 activator' story the compound is usually sold with, and a credit to the paper for printing it.

What separates this from a treatment for ACM?

Everything clinical. The model compresses the disease into three weeks in mice; human PKP2 disease unfolds over years, and the concealed-stage risk that matters — sudden arrhythmia — was not an endpoint here. Honokiol was tested against protein patterns, not survival, rhythm outcomes or heart function in this study, and supplement-grade honokiol products are neither dosed nor quality-controlled like a trial drug. What the study genuinely adds is timing and a candidate lever: mitochondrial alteration is early enough to be an intervention target rather than a consequence, and a mitochondria-engaging compound can move the early pattern. ACM still has no therapy proven to prevent arrhythmia or halt progression — this is a reason for trials, not a substitute for them.

Where the evidence stands

• Established: PKP2 mutations are the most common genetic cause of arrhythmogenic cardiomyopathy; the early concealed stage carries high arrhythmia risk without symptoms; and no therapy is proven to prevent arrhythmia or halt ACM progression.
• Preliminary: In an inducible Pkp2-knockout mouse model (Nature Cardiovascular Research, Oct 29, 2026), time-resolved proteomics (6,527 proteins, 72 samples, 21 days) placed mitochondrial remodeling among the earliest changes, and 14 days of honokiol shifted right-ventricular protein abundances against the disease trajectory, engaging inner-mitochondrial-membrane proteins including complex III components.
• Absent: Human evidence of any kind, arrhythmia or survival endpoints, long-term disease-course data, and any established honokiol dose or product for ACM.